Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared on LinkedIn:
“As a medical oncologist, I’m incredibly passionate about the potential of MRD testing to transform oncology care and enable truly personalized treatment for our patients with cancer.
I’m excited to support and be part of this collaboration between Fox Chase Cancer Center and Labcorp to generate clinical evidence for an ultra‑sensitive MRD assay in early‑stage NSCLC.
Building robust clinical data is a critical step toward bringing this impactful diagnostic tool into routine clinical practice for patients.”
Learn more about the Fox Chase and Labcorp collaboration here.
Other articles featuring Heidi Ko on OncoDaily.